Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Rubin, 2001, The basic biology of HER2, Ann Oncol, 12, S3, 10.1093/annonc/12.suppl_1.S3 Yarden, 2007, SnapShot: EGFR signaling pathway, Cell, 131, 1018, 10.1016/j.cell.2007.11.013 Yarden, 2001, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2, 127, 10.1038/35052073 Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Ross, 2001, The HER-2/neu oncogene in tumors of the gastrointestinal tract, Cancer Invest, 19, 554, 10.1081/CNV-100103852 Lassus, 2006, Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma, J Mol Med, 84, 671, 10.1007/s00109-006-0054-4 Kameda, 1990, Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification, Cancer Res, 50, 8002 Carter, 1992, Humanization of an anti-p185HER2 antibody for human cancer therapy, Proc Natl Acad Sci USA, 89, 4285, 10.1073/pnas.89.10.4285 Buzdar, 2005, Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol, 23, 3676, 10.1200/JCO.2005.07.032 Hudis, 2007, Trastuzumab–mechanism of action and use in clinical practice, N Engl J Med, 357, 39, 10.1056/NEJMra043186 Disis, 2002, Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines, J Clin Oncol, 20, 2624, 10.1200/JCO.2002.06.171 Peoples, 2005, Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients, J Clin Oncol, 23, 7536, 10.1200/JCO.2005.03.047 Morse, 2007, Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2, J Transl Med, 5, 42, 10.1186/1479-5876-5-42 Bernhard, 2008, Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer, Cancer Immunol Immunother, 57, 271, 10.1007/s00262-007-0355-7 Dudley, 2005, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J Clin Oncol, 23, 2346, 10.1200/JCO.2005.00.240 Dudley, 2008, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens, J Clin Oncol, 26, 5233, 10.1200/JCO.2008.16.5449 Vera, 2009, Immunotherapy of human cancers using gene modified T lymphocytes, Curr Gene Ther, 9, 396, 10.2174/156652309789753338 Sadelain, 2003, Targeting tumours with genetically enhanced T lymphocytes, Nat Rev Cancer, 3, 35, 10.1038/nrc971 Murphy, 2005, Gene modification strategies to induce tumor immunity, Immunity, 22, 403, 10.1016/j.immuni.2005.03.007 Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003 Johnson, 2009, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714 Eshhar, 2008, The T-body approach: redirecting T cells with antibody specificity, Handb Exp Pharmacol, 329, 10.1007/978-3-540-73259-4_14 Eshhar, 1993, Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or zeta subunits of the immunoglobulin and T-cell receptors, Proc Natl Acad Sci USA, 90, 720, 10.1073/pnas.90.2.720 Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma, Nat Med, 14, 1264, 10.1038/nm.1882 Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin Cancer Res, 12, 6106, 10.1158/1078-0432.CCR-06-1183 Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24, e20, 10.1200/JCO.2006.05.9964 Park, 2007, Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma, Mol Ther, 15, 825, 10.1038/sj.mt.6300104 Zhao, 2009, A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity, J Immunol, 183, 5563, 10.4049/jimmunol.0900447 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Beano, 2008, Correlation between NK function and response to trastuzumab in metastatic breast cancer patients, J Transl Med, 6, 25, 10.1186/1479-5876-6-25 Gennari, 2004, Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2, Clin Cancer Res, 10, 5650, 10.1158/1078-0432.CCR-04-0225 Varchetta, 2007, Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2, Cancer Res, 67, 11991, 10.1158/0008-5472.CAN-07-2068 Mani, 2009, A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab, Breast Cancer Res Treat, 117, 83, 10.1007/s10549-008-0251-7 Parihar, 2004, A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon γ production in a subset of patients, Clin Cancer Res, 10, 5027, 10.1158/1078-0432.CCR-04-0265 Fisher, 1989, Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma, J Clin Oncol, 7, 250, 10.1200/JCO.1989.7.2.250 Taraban, 2002, Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses, Eur J Immunol, 32, 3617, 10.1002/1521-4141(200212)32:12<3617::AID-IMMU3617>3.0.CO;2-M Wang, 2009, Immune regulation by 4-1BB and 4-1BBL: complexities and challenges, Immunol Rev, 229, 192, 10.1111/j.1600-065X.2009.00765.x Zhong, 2009, Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI(3)kinase/AKT/Bcl-X(L) Activation and CD8(+) T Cell-mediated Tumor Eradication, Mol Ther Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol Ther, 17, 1453, 10.1038/mt.2009.83 Carpenito, 2009, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, Proc Natl Acad Sci USA, 106, 3360, 10.1073/pnas.0813101106 Till, 2008, Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood, 112, 2261, 10.1182/blood-2007-12-128843 Scheving, 2006, The emergence of ERBB2 expression in cultured rat hepatocytes correlates with enhanced and diversified EGF-mediated signaling, Am J Physiol Gastrointest Liver Physiol, 291, G16, 10.1152/ajpgi.00328.2005 Lenz, 2007, Systemic inflammation after trauma, Injury, 38, 1336, 10.1016/j.injury.2007.10.003 Wang, 2008, The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome, Am J Emerg Med, 26, 711, 10.1016/j.ajem.2007.10.031 Chatenoud, 1990, In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids, Transplantation, 49, 697, 10.1097/00007890-199004000-00009 Sgro, 1995, Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review, Toxicology, 105, 23, 10.1016/0300-483X(95)03123-W Stebbings, 2007, “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics, J Immunol, 179, 3325, 10.4049/jimmunol.179.5.3325 Stebbings, 2009, Safety of biologics, lessons learnt from TGN1412, Curr Opin Biotechnol, 20, 673, 10.1016/j.copbio.2009.10.002 Suntharalingam, 2006, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412, N Engl J Med, 355, 1018, 10.1056/NEJMoa063842 Weiner, 1995, Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fcγ RIII, Cancer Res, 55, 4586 Akalin, 2001, Gene polymorphisms and transplantation, Curr Opin Immunol, 13, 572, 10.1016/S0952-7915(00)00261-2 Girnita, 2008, Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation, Clin Lab Med, 28, 423, 10.1016/j.cll.2008.08.002 Marshall, 2001, The role of cytokine polymorphisms in rejection after solid organ transplantation, Genes Immun, 2, 297, 10.1038/sj.gene.6363795 Tischendorf, 2007, The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6, Int J Immunogenet, 34, 413, 10.1111/j.1744-313X.2007.00712.x Stanilova, 2006, Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility, Intensive Care Med, 32, 260, 10.1007/s00134-005-0022-4 Cope, 2004, Tumor lysis syndrome, Clin J Oncol Nurs, 8, 415, 10.1188/04.CJON.415-416 Cohen, 2005, Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR, J Immunol, 175, 5799, 10.4049/jimmunol.175.9.5799 Theoret, 2008, Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells, Hum Gene Ther, 19, 1219, 10.1089/hum.2008.083 Press, 1990, Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues, Oncogene, 5, 953 Lotem, 2006, Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors, J Immunother, 29, 616, 10.1097/01.cji.0000211312.36363.56